Last reviewed · How we verify
NCT05145166
Safety Study of Live Attenuated Mumps Vaccines in Junior High School Students Under 14 Years Old
trial testing Safety group in Mumps in 10,000 participants. Completed in 25 March 2021.
6 November 2020
Quick facts
| Lead sponsor | Sinovac (Dalian) Vaccine Technology Co., Ltd. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 10,000 |
| Start date | 6 October 2020 |
| Primary completion | 6 November 2020 |
| Estimated completion | 25 March 2021 |
| Sites | 3 locations across China |
Drugs / interventions tested
- Safety group — full drug profile →
Conditions studied
- Mumps — all drugs for Mumps →
Sponsor
Sinovac (Dalian) Vaccine Technology Co., Ltd. — full company profile →
Who can join
Under 14, any sex, with Mumps. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study of live attenuated mumps vaccines is an observational study in which active monitoring and passive monitoring were combined to conduct safety observation.The live attenuated mumps vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.The purpose of this study is to evaluate the safety of live attenuated mumps vaccines after large-scale application and accumulate safety data for the application of live attenuated mumps vaccines,and provide scientific basis for the formulation of vaccine immunization prevention strategies.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Safety analysis of a live attenuated mumps vaccine in healthy adolescents in China: A phase 4, observational, open-label trial.
Hu W, Jia N, Meng W, Zhou T, et al · · 2023 · cited 1× · PMID 37733724 · DOI 10.1371/journal.pone.0291730
Verify or expand the search:
- PubMed search for NCT05145166
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Mumps
Currently open trials in the same condition.
- NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective · recruiting
Other Sinovac (Dalian) Vaccine Technology Co., Ltd. trials
Trials by the same sponsor.
- NCT07473427 — Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Aged 1~12 Years: A Single-armed Brid · Phase 3 · not yet recruiting
- NCT07475000 — Second Dose of Varicella Vaccine in Healthy Children · Phase 3 · recruiting
- NCT06482216 — Correlation of Protection Against Varicella in an Exploratory Study · not yet recruiting
- NCT06987942 — Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Spli · Phase 4 · completed
- NCT06994052 — Study on Booster Immunization With Varicella Vaccine at Different Intervals · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05145166 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sinovac (Dalian) Vaccine Technology Co., Ltd.
- Last refreshed: 6 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05145166.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing